214 related articles for article (PubMed ID: 33779053)
1. Disparities in male versus female oncologic outcomes following bladder preservation: A population-based cohort study.
Ballas LK; Navarro S; Luo C; Fossum CC; Farias A; Daneshmand S; Groshen S
Cancer Med; 2021 May; 10(9):3004-3012. PubMed ID: 33779053
[TBL] [Abstract][Full Text] [Related]
2. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
[TBL] [Abstract][Full Text] [Related]
3. Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival.
Lee CY; Yang KL; Ko HL; Huang RY; Tsai PP; Chen MT; Lin YC; Hwang TI; Juang GD; Chi KH
Radiat Oncol; 2014 Sep; 9():213. PubMed ID: 25248470
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Transurethral Resection plus Systemic Chemotherapy as Definitive Treatment for Muscle Invasive Bladder Cancer in Population Level Data.
Audenet F; Waingankar N; Ferket BS; Niglio SA; Marqueen KE; Sfakianos JP; Galsky MD
J Urol; 2018 Nov; 200(5):996-1004. PubMed ID: 29879397
[TBL] [Abstract][Full Text] [Related]
5. Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials.
Arcangeli G; Strigari L; Arcangeli S
Crit Rev Oncol Hematol; 2015 Sep; 95(3):387-96. PubMed ID: 25934521
[TBL] [Abstract][Full Text] [Related]
6. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
Kulkarni GS; Hermanns T; Wei Y; Bhindi B; Satkunasivam R; Athanasopoulos P; Bostrom PJ; Kuk C; Li K; Templeton AJ; Sridhar SS; van der Kwast TH; Chung P; Bristow RG; Milosevic M; Warde P; Fleshner NE; Jewett MAS; Bashir S; Zlotta AR
J Clin Oncol; 2017 Jul; 35(20):2299-2305. PubMed ID: 28410011
[TBL] [Abstract][Full Text] [Related]
7. Bladder preservation for localized muscle-invasive bladder cancer: the survival impact of local utilization rates of definitive radiotherapy.
Kozak KR; Hamidi M; Manning M; Moody JS
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):e197-204. PubMed ID: 22401916
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy.
Krasnow RE; Drumm M; Roberts HJ; Niemierko A; Wu CL; Wu S; Zhang J; Heney NM; Wszolek MF; Blute ML; Feldman AS; Lee RJ; Zietman AL; Shipley WU; Efstathiou JA
Eur Urol; 2017 Jul; 72(1):54-60. PubMed ID: 28040351
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
[TBL] [Abstract][Full Text] [Related]
10. Comparative survival analysis of bladder preservation therapy versus radical cystectomy in muscle-invasive bladder cancer.
Kang NW; Feng YH; Lin KL; Chen YC; Ho CH; Yang CC
Cancer Med; 2024 Jan; 13(2):e6972. PubMed ID: 38379322
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Tri-Modality Therapy with Bladder Preservation for Selective Muscle-Invasive Bladder Cancer.
Zhiyu Z; Qi Z; Zhen S; Jun O; Jianglei Z
Technol Cancer Res Treat; 2021; 20():15330338211062323. PubMed ID: 34816789
[No Abstract] [Full Text] [Related]
12. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W
Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.
Mak RH; Hunt D; Shipley WU; Efstathiou JA; Tester WJ; Hagan MP; Kaufman DS; Heney NM; Zietman AL
J Clin Oncol; 2014 Dec; 32(34):3801-9. PubMed ID: 25366678
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness of Bladder-preserving Tri-modality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer.
Royce TJ; Feldman AS; Mossanen M; Yang JC; Shipley WU; Pandharipande PV; Efstathiou JA
Clin Genitourin Cancer; 2019 Feb; 17(1):23-31.e3. PubMed ID: 30482661
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.
Jiang DM; Jiang H; Chung PWM; Zlotta AR; Fleshner NE; Bristow RG; Berlin A; Kulkarni GS; Alimohamed NS; Lo G; Sridhar SS
Clin Genitourin Cancer; 2019 Feb; 17(1):38-45. PubMed ID: 30686350
[TBL] [Abstract][Full Text] [Related]
16. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Outcomes in Patients With Muscle-invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder Preservation.
Zhong J; Switchenko J; Jegadeesh NK; Cassidy RJ; Gillespie TW; Master V; Nieh P; Alemozaffar M; Kucuk O; Carthon B; Filson CP; Bilen MA; Jani AB
Am J Clin Oncol; 2019 Jan; 42(1):36-41. PubMed ID: 29912804
[TBL] [Abstract][Full Text] [Related]
18. Concurrent chemotherapy is associated with improved survival in elderly patients with bladder cancer undergoing radiotherapy.
Korpics MC; Block AM; Martin B; Hentz C; Gaynor ER; Henry E; Harkenrider MM; Solanki AA
Cancer; 2017 Sep; 123(18):3524-3531. PubMed ID: 28581675
[TBL] [Abstract][Full Text] [Related]
19. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
[TBL] [Abstract][Full Text] [Related]
20. A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC).
Arcangeli G; Arcangeli S; Strigari L
Crit Rev Oncol Hematol; 2015 Apr; 94(1):105-15. PubMed ID: 25541350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
